Morgan Stanley analyst David Lewis maintained a Hold rating on Becton Dickinson (NYSE: BDX) today and set a price target of $280. The company’s shares closed yesterday at $258.70, close to its 52-week high of $265.87.
According to TipRanks.com, Lewis is a 5-star analyst with an average return of 15.4% and a 74.4% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Intuitive Surgical, and Haemonetics Corp.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Becton Dickinson with a $271.70 average price target.
Becton Dickinson’s market cap is currently $69.22B and has a P/E ratio of 111.51. The company has a Price to Book ratio of 3.24.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Becton, Dickinson & Co. is a global medical technology company. The company is engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.